| pubmed-article:3008313 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3008313 | lifeskim:mentions | umls-concept:C0022671 | lld:lifeskim |
| pubmed-article:3008313 | lifeskim:mentions | umls-concept:C0677582 | lld:lifeskim |
| pubmed-article:3008313 | lifeskim:mentions | umls-concept:C0596545 | lld:lifeskim |
| pubmed-article:3008313 | lifeskim:mentions | umls-concept:C0021149 | lld:lifeskim |
| pubmed-article:3008313 | lifeskim:mentions | umls-concept:C0445202 | lld:lifeskim |
| pubmed-article:3008313 | lifeskim:mentions | umls-concept:C0355642 | lld:lifeskim |
| pubmed-article:3008313 | pubmed:dateCreated | 1986-4-30 | lld:pubmed |
| pubmed-article:3008313 | pubmed:abstractText | Incidence and clinical symptomatology of CMV-infection was investigated in 83 patients, who received cadaveric renal transplants in 1982 and 1983. CMV-antibody status was determined using an ELISA-technique, 43 of the 83 patients (52%) were seronegative, and 40 (48%) were seropositive for CMV before transplantation. Seroconversion (i.e. primary CMV-infection) or an increase in titre (i.e. reactivation or reinfection) was found in 18 cases (42% and 45%, respectively) in both groups. 89% of all infections occurred within the first 3 months. Clinical symptomatology was much more severe in the group with primary CMV-infection; all cases with atypical pneumonia (n = 8) and both fatal cases belonged to this group. Preformed CMV-antibodies thus appeared to prevent severe syndromes associated with CMV-infection. Therefore a randomized controlled study was started in 1984 in order to investigate the efficacy of an i.v. applicable CMV-hyperimmunoglobulin passively administered prior to the transplant procedure. The passive immunization was not capable of preventing CMV-infection in every case: 2 (late) seroconversions did occur, but in both cases subclinical infections were diagnosed, whereas in the control group CMV-infections were regularly associated with typical clinical complications (prolonged fever, liver damage, leucopenia etc.). Thus prophylactic CMV-hyperimmunoglobulin seems to be capable of preventing the occurrence of severe CMV-syndromes post transplantation. The study is being continued. | lld:pubmed |
| pubmed-article:3008313 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3008313 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3008313 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3008313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3008313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3008313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3008313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3008313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3008313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3008313 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3008313 | pubmed:issn | 0300-8886 | lld:pubmed |
| pubmed-article:3008313 | pubmed:author | pubmed-author:SchoeppeWW | lld:pubmed |
| pubmed-article:3008313 | pubmed:author | pubmed-author:ScheuermannE... | lld:pubmed |
| pubmed-article:3008313 | pubmed:author | pubmed-author:BechsteinP... | lld:pubmed |
| pubmed-article:3008313 | pubmed:author | pubmed-author:FassbinderWW | lld:pubmed |
| pubmed-article:3008313 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3008313 | pubmed:volume | 92 | lld:pubmed |
| pubmed-article:3008313 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3008313 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3008313 | pubmed:pagination | 23-8 | lld:pubmed |
| pubmed-article:3008313 | pubmed:dateRevised | 2009-11-11 | lld:pubmed |
| pubmed-article:3008313 | pubmed:meshHeading | pubmed-meshheading:3008313-... | lld:pubmed |
| pubmed-article:3008313 | pubmed:meshHeading | pubmed-meshheading:3008313-... | lld:pubmed |
| pubmed-article:3008313 | pubmed:meshHeading | pubmed-meshheading:3008313-... | lld:pubmed |
| pubmed-article:3008313 | pubmed:meshHeading | pubmed-meshheading:3008313-... | lld:pubmed |
| pubmed-article:3008313 | pubmed:meshHeading | pubmed-meshheading:3008313-... | lld:pubmed |
| pubmed-article:3008313 | pubmed:meshHeading | pubmed-meshheading:3008313-... | lld:pubmed |
| pubmed-article:3008313 | pubmed:meshHeading | pubmed-meshheading:3008313-... | lld:pubmed |
| pubmed-article:3008313 | pubmed:meshHeading | pubmed-meshheading:3008313-... | lld:pubmed |
| pubmed-article:3008313 | pubmed:meshHeading | pubmed-meshheading:3008313-... | lld:pubmed |
| pubmed-article:3008313 | pubmed:meshHeading | pubmed-meshheading:3008313-... | lld:pubmed |
| pubmed-article:3008313 | pubmed:meshHeading | pubmed-meshheading:3008313-... | lld:pubmed |
| pubmed-article:3008313 | pubmed:meshHeading | pubmed-meshheading:3008313-... | lld:pubmed |
| pubmed-article:3008313 | pubmed:meshHeading | pubmed-meshheading:3008313-... | lld:pubmed |
| pubmed-article:3008313 | pubmed:year | 1985 | lld:pubmed |
| pubmed-article:3008313 | pubmed:articleTitle | Incidence of cytomegalovirus-infection after renal transplantation and first experiences with prophylactic hyperimmunoglobulin. | lld:pubmed |
| pubmed-article:3008313 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3008313 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:3008313 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
